




INVITATION

OVarian Cancer Advances Summit - 2021



A multi-disciplinary approach to managing patients with Ovarian Cancer

[Click To Register](#) 

Date	Friday 3 rd December	Saturday 4 th December
Location	<ul style="list-style-type: none"> • Online Webinar • Sydney - Pullman Quay Grand Sydney Harbour • Melbourne - Crowne Plaza 	Online Webinar
Time	QLD — 5:00 pm - 8:00 pm NSW — 6:00 pm - 9:00 pm VIC — 6:00 pm - 9:00 pm SA — 5:30 pm - 8:30 pm WA — 3:00 pm - 6:00 pm NZ — 8:00 pm - 11:00 pm	QLD — 8:00 am - 3:30 pm NSW — 9:00 am - 4:30 pm VIC — 9:00 am - 4:30 pm SA — 8:30 am - 4:00 pm WA — 6:00 am - 1:30 pm NZ — 11:00 am - 6:30 pm

Hosted by an independent steering committee:



Prof. Michael Friedlander
(Medical Oncologist)



Prof. Clare Scott
(Medical Oncologist/Ovarian cancer researcher)



A/Prof. Chee Lee
(Medical Oncologist/Ovarian cancer researcher)

International Speaker Panel:



Prof. Jonathan Ledermann
(Medical Oncologist - United Kingdom)



Prof. Robert Coleman
(Gynae Oncologist - USA)



Prof. Andreas du Bois
(Gynae Oncologist - Germany)



Prof. Christina Fotopolou
(Gynae Oncologist - UK)



A/Prof. David Tan
(Medical Oncologist - Singapore)



Prof. Michael Bookman
(Medical Oncologist - USA)

TIME (AEDT)	AGENDA	SPEAKERS
Friday 3rd December		
17:30 - 18:00	Arrival & Registration	
18:00 - 18:30	Dinner	
18:30 - 19:30	Opening remarks	Michael Friedlander
	Debate (The Aye team vs the Nay team)	
	Upfront or interval debulking surgery for patients with advanced ovarian cancer?	Aye: Christina Fotopolou (UK) + Andreas Du Bois (Ger) Nay: Jim Nicklin + Alison Brand
	Have the indications for neoadjuvant chemotherapy become too liberal	
19:30 - 19:45	Break	
19:45 - 20:45	Re-convene and speaker introduction	Chee Lee
	Will targeted therapies for ovarian cancer diminish the role of the Gynaecological Oncologist over the next decade - Including Q&A	Jonathan Ledermann (UK)
20:45 - 21:00	Close	Michael Friedlander, Clare Scott, Chee Lee
Saturday 4th December		
09:00 - 09:15	Welcome and introductions	Michael Friedlander
09:15 - 09:45	Management of menopause after cancer	Martha Hickey
09:45 - 10:30	Advances in the management of High-Grade Serous Ovarian cancer - A year in review (SGO, ASCO, ESMO)	Michael Bookman (USA)
10:30 - 10:45	Morning Tea	
	Re-convene and facilitate introductions	Chee Lee
10:45 - 11:05	Laparoscopy to determine upfront vs interval debulking - triage methodology	Andreas Obermair
11:05 - 11:25	The role of the molecular pathologist in the management of HGSOc - somatic testing and HRD assays	Stephen Fox
11:25 - 11:55	Secondary debulking surgery - can we identify which patients should be offered surgery	Robert Coleman (USA)
11:55 - 12:25	NACT-IDS: Molecular considerations impacting patient outcomes (BRCAm vs BRCA wt)	Liz Christie
12:25 - 13:00	Lunch	
	Re-convene and facilitate introductions	Michael Friedlander
13:00 - 13:30	HR Proficient HGSOc - the next frontier	Clare Scott
13:30 - 14:00	Advances in the management of non High-Grade Serous Ovarian cancer - A year in review	David Tan (SG)
14:00 - 14:45	MDT Panel case discussions - Emerging therapy options in HGSOc cancer (Mono vs doublet vs triplet)	George Au-Yeung
14:45 - 15:00	Afternoon Tea	
	Re-convene and facilitate introductions	Clare Scott
15:00 - 15:45	MDT Panel case discussion	Chee Lee
15:45 - 16:15	Survivorship - Improving outcomes for patients with HGSOc - what have we learned from the OPAL study	Penny Webb
16:15 - 16:30	Close	Michael Friedlander, Clare Scott, Chee Lee

Please Scan



or

Click To Register



Attendance to dinner meetings is subject to availability.

HEALTH & SAFETY: AstraZeneca values your health and safety. We choose to use venues and suppliers who have COVID-Safe plans in place. Venues may require you to register on arrival for contact tracing reasons or to show current vaccination status, and adherence to other COVID safe measures. All local regulations and laws around social distancing, vaccination status, and attendee numbers must be adhered to by all attendees. Please ensure that you have registered, as we may not be able to accommodate you if we have reached these limits. There will be access to hand sanitiser, tissues and face masks should you need/wish to use these. If you are unwell, tested positive for, or had any known symptoms, of COVID-19 in the last 14 days, please ensure you stay home. The meeting is organised and funded by AstraZeneca. Attendance at AstraZeneca educational meetings is by invitation only and is limited to registered Healthcare Professionals. The company seeks no commitment from external stakeholders to take any action as a result of the invitation or related support. **PRIVACY STATEMENT:** Your personal information ("Information") will be collected and used by AstraZeneca Pty Ltd ("AstraZeneca") for the purpose of administration of this webcast, for follow-up purposes and for any other purpose described in AstraZeneca's Privacy Policy (see below for link). AstraZeneca may disclose your Information to third parties such as our related entities or service providers (including IT support/service providers), some of which may be located overseas including in the US, European Union and Asia Pacific. Please refer to our [Privacy Policy](https://www.astrazeneca.com.au/privacy-policy.html) (<https://www.astrazeneca.com.au/privacy-policy.html>) for more information about how your Information is handled and how you may seek to access or correct your Information, or submit a privacy complaint.

AstraZeneca Pty. Ltd. ABN 54 009 682 311. 66 Talavera Road, Macquarie Park, NSW 2113. www.astrazeneca.com.au. For Medical Information enquiries or to report an adverse event or product quality complaint: Telephone 1800 805 342 or via <https://contactazmedical.astrazeneca.com> Or email Medical Information enquiries to medinfo.australia@astrazeneca.com. AU-12322, E-011607, November 2021.